These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22065318)

  • 41. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
    Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
    Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Precise anatomical resection based on structures of nerve and fibrous tissue around the superior mesenteric artery for mesopancreas dissection in pancreaticoduodenectomy for pancreatic cancer.
    Nagakawa Y; Yi SQ; Takishita C; Sahara Y; Osakabe H; Kiya Y; Yamaguchi H; Miwa Y; Sato I; Tsuchida A
    J Hepatobiliary Pancreat Sci; 2020 Jun; 27(6):342-351. PubMed ID: 32048456
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases.
    Galindo J; Gabrielli M; Guerra JF; Cassina JC; Garrido M; Jarufe N; Borghero Y; Madrid J; Zoroquiain P; Roa JC; Martínez J
    World J Surg Oncol; 2013 Feb; 11():37. PubMed ID: 23379413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma.
    Habermehl D; Brecht IC; Bergmann F; Rieken S; Werner J; Büchler MW; Springfeld C; Jäger D; Debus J; Combs SE
    World J Surg Oncol; 2015 Apr; 13():149. PubMed ID: 25889749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
    Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO
    Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
    Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
    Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lymph node involvement beyond peripancreatic region in pancreatic head cancers: when results belie expectations.
    Golse N; Lebeau R; Lombard-Bohas C; Hervieu V; Ponchon T; Adham M
    Pancreas; 2013 Mar; 42(2):239-48. PubMed ID: 23038054
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
    Kim BH; Kim K; Jang JY; Kwon W; Kim H; Lee KH; Oh DY; Kim H; Lee KB; Chie EK
    Eur J Surg Oncol; 2020 Nov; 46(11):2122-2130. PubMed ID: 32782200
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implications of Prolonged Time to Pancreaticoduodenectomy After Neoadjuvant Chemoradiation.
    Teng A; Nguyen T; Bilchik AJ; O'Connor V; Lee DY
    J Surg Res; 2020 Jan; 245():51-56. PubMed ID: 31401247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
    Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
    Kwon D; McFarland K; Velanovich V; Martin RC
    Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
    Cunningham SC; Cusnir M; Burdick RK; Van Echo DA; Moesinger R
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):741-2; discussion 743. PubMed ID: 16258479
    [No Abstract]   [Full Text] [Related]  

  • 53. Pancreaticoduodenectomy with right-oblique posterior dissection of superior mesenteric nerve plexus is logical procedure for pancreatic cancer with extrapancreatic nerve plexus invasion.
    Nagakawa Y; Hosokawa Y; Osakabe H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasahara K; Kazuhiko K; Saito K; Tsuchida A
    Hepatogastroenterology; 2014; 61(136):2371-6. PubMed ID: 25699385
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inferior Infracolic 'Superior Mesenteric Artery First' Approach with a No-Touch Isolation Surgical Technique in Patients with a Borderline Resectable Cancer of the Pancreatic Head.
    Zhu J; Han D; Li X; Pan F; Ma J; Kou J; Fan H; Lang R; He Q
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):976-980. PubMed ID: 27600620
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.
    Barrord M; Ahmad S; Patel S; Olowokure O; Sussman J; Smith M; Poreddy S; Esslinger H; Latif T; Choe K; Kharofa J
    Pancreas; 2020 Aug; 49(7):941-946. PubMed ID: 32658077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Posterior Superior Mesenteric Artery (SMA) First Approach vs. Standard Pancreaticoduodenectomy in Patients with Resectable Periampullary Cancers: a Prospective Comparison Focusing on Circumferential Resection Margins.
    Pal S; George J; Singh AN; Mathur S; Dash NR; Garg P; Sahni P; Chattopadhyay TK
    J Gastrointest Cancer; 2018 Sep; 49(3):252-259. PubMed ID: 28315190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
    Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
    Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy.
    Chao YJ; Sy ED; Hsu HP; Shan YS
    BMC Surg; 2014 Sep; 14():72. PubMed ID: 25258022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomized controlled trial of 354 patients with pancreatic ductal adenocarcinoma.
    Hirono S; Kawai M; Okada KI; Fujii T; Sho M; Satoi S; Amano R; Eguchi H; Mataki Y; Nakamura M; Matsumoto I; Baba H; Tani M; Kawabata Y; Nagakawa Y; Yamada S; Murakami Y; Shimokawa T; Yamaue H
    Trials; 2018 Nov; 19(1):613. PubMed ID: 30409152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer.
    Magnin V; Moutardier V; Giovannini MH; Lelong B; Giovannini M; Viret F; Monges G; Bardou VJ; Alzieu C; Delpero JR
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1300-4. PubMed ID: 12654441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.